- Home
- CLRB vs OMGA Comparison
CLRB vs OMGA Comparison
Compare CLRB & OMGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- OMGA
- Stock Information
- Founded
- CLRB 2002
- OMGA 2017
- Country
- CLRB United States
- OMGA United States
- Employees
- CLRB N/A
- OMGA N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- OMGA Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- OMGA Health Care
- Exchange
- CLRB Nasdaq
- OMGA Nasdaq
- Market Cap
- CLRB 76.0M
- OMGA 74.5M
- IPO Year
- CLRB N/A
- OMGA 2021
- Fundamental
- Price
- CLRB $1.86
- OMGA $0.82
- Analyst Decision
- CLRB Strong Buy
- OMGA Strong Buy
- Analyst Count
- CLRB 2
- OMGA 5
- Target Price
- CLRB $21.00
- OMGA $9.20
- AVG Volume (30 Days)
- CLRB 289.0K
- OMGA 450.6K
- Earning Date
- CLRB 11-18-2024
- OMGA 11-14-2024
- Dividend Yield
- CLRB N/A
- OMGA N/A
- EPS Growth
- CLRB N/A
- OMGA N/A
- EPS
- CLRB N/A
- OMGA N/A
- Revenue
- CLRB N/A
- OMGA $8,095,000.00
- Revenue This Year
- CLRB N/A
- OMGA $127.25
- Revenue Next Year
- CLRB N/A
- OMGA N/A
- P/E Ratio
- CLRB N/A
- OMGA N/A
- Revenue Growth
- CLRB N/A
- OMGA 185.04
- 52 Week Low
- CLRB $1.82
- OMGA $0.77
- 52 Week High
- CLRB $4.45
- OMGA $6.30
- Technical
- Relative Strength Index (RSI)
- CLRB 30.70
- OMGA 36.06
- Support Level
- CLRB $1.97
- OMGA $1.06
- Resistance Level
- CLRB $2.18
- OMGA $1.17
- Average True Range (ATR)
- CLRB 0.10
- OMGA 0.11
- MACD
- CLRB -0.01
- OMGA -0.02
- Stochastic Oscillator
- CLRB 8.11
- OMGA 2.25
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.